The Infectious Disease Diagnostics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.7 million individuals were HIV positive in 2020, out of which 36 million were adults and 1.7 million were children between the ages of 0 and 14. Furthermore, more than half (53%) were females. 1.5 million new HIV cases were recorded in 2020 worldwide. Further, Hepatitis is a viral infection that results in liver inflammation. Hepatitis viruses come in five primary strains: A, B, C, D, and E. As per the World Health Organization (WHO), about 58 million individuals worldwide have chronic hepatitis C virus infection, and 1.5 million new infections occur each year.
According to WHO, After COVID-19, tuberculosis (TB) is the second most common infectious disease in the world and the thirteenth leading cause of death overall. As per WHO, 1.5 million deaths were caused due to TB in 2020 (including 214,000 people affected by HIV). WHO anticipated that 10 million individuals, including 1.1 million children, 3.3 million women, and 5.6 million men, would be affected by TB worldwide in 2020. All countries and age ranges are affected by TB. In addition, 30 countries with heavy TB burdens accounted for 86% of new TB cases in 2020. Two-thirds of the total is made up of eight countries, with India topping the list, then China, the Philippines, Nigeria, Pakistan, Indonesia, Bangladesh, and South Africa.
Moreover, the growing prevalence of healthcare-acquired infections (HAIs) globally. For instance, according to the Centers for Disease Control (CDC), HAIs alone in American hospitals are considered to be responsible for 1.7 million infections and 99,000 associated deaths per year. Of these infections, urinary tract infections make up 32% of all healthcare-acquired infections, followed by surgical site infections (22%), pneumonia (15%), and bloodstream infections (14%).
Growing prevalence of infectious diseases in developed and emerging nations will positively impact the growth of the infectious disease diagnostics market. The diagnosis and management of these diseases are key responsible factors for the rising number of prescriptions for diagnostic tests for infectious diseases. Large-scale population-based diagnostic testing is required for the prevention and control measures of COVID-19.
Growing Prevalence of Infectious Diseases, And Shift in Focus from Centralized Laboratories to Decentralized POC Testing Are Driving the Market Growth
Growing prevalence of infectious diseases is anticipated to drive the growth of the infectious disease diagnostics market over the forecast period. For instance, on February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases of coronavirus disease 2019 in locations outside mainland China and the number of associated deaths was 2,462.According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.7 million individuals were HIV positive in 2020, out of which 36 million were adults and 1.7 million were children between the ages of 0 and 14. Furthermore, more than half (53%) were females. 1.5 million new HIV cases were recorded in 2020 worldwide. Further, Hepatitis is a viral infection that results in liver inflammation. Hepatitis viruses come in five primary strains: A, B, C, D, and E. As per the World Health Organization (WHO), about 58 million individuals worldwide have chronic hepatitis C virus infection, and 1.5 million new infections occur each year.
According to WHO, After COVID-19, tuberculosis (TB) is the second most common infectious disease in the world and the thirteenth leading cause of death overall. As per WHO, 1.5 million deaths were caused due to TB in 2020 (including 214,000 people affected by HIV). WHO anticipated that 10 million individuals, including 1.1 million children, 3.3 million women, and 5.6 million men, would be affected by TB worldwide in 2020. All countries and age ranges are affected by TB. In addition, 30 countries with heavy TB burdens accounted for 86% of new TB cases in 2020. Two-thirds of the total is made up of eight countries, with India topping the list, then China, the Philippines, Nigeria, Pakistan, Indonesia, Bangladesh, and South Africa.
Moreover, the growing prevalence of healthcare-acquired infections (HAIs) globally. For instance, according to the Centers for Disease Control (CDC), HAIs alone in American hospitals are considered to be responsible for 1.7 million infections and 99,000 associated deaths per year. Of these infections, urinary tract infections make up 32% of all healthcare-acquired infections, followed by surgical site infections (22%), pneumonia (15%), and bloodstream infections (14%).
Growing prevalence of infectious diseases in developed and emerging nations will positively impact the growth of the infectious disease diagnostics market. The diagnosis and management of these diseases are key responsible factors for the rising number of prescriptions for diagnostic tests for infectious diseases. Large-scale population-based diagnostic testing is required for the prevention and control measures of COVID-19.
What Questions Should You Ask before Buying a Market Research Report?
- How is the infectious disease diagnostics market evolving?
- What is driving and restraining the infectious disease diagnostics market?
- How will each infectious disease diagnostics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
- How will the market shares for each infectious disease diagnostics submarket develop from 2022 to 2032?
- What will be the main driver for the overall market from 2022 to 2032?
- Will leading infectious disease diagnostics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
- Who are the leading players and what are their prospects over the forecast period?
- What are the infectious disease diagnostics research projects for these leading companies?
- How will the industry evolve during the period between 2022 and 2032? What are the implications of infectious disease diagnostics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the infectious disease diagnostics market?
- Where is the infectious disease diagnostics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Infectious Disease Diagnostics Market today, and over the next 10 years:
- Our 32-page report provides 120 tables and 201 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2032 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising infectious disease diagnostics prices and recent developments.
Segments Covered in the Report
Product
- Instrument
- Reagents, Kits, and Consumables
- Software & Services
Type of Testing
- Laboratory Testing
- POC Testing
Technology
- Immunodiagnostics
- Polymerase Chain Reaction (PCR)
- Real-time PCR/qPCR
- Reverse Transcriptase PCR (RT-PCR)
- Multiplex PCR
- Others
- DNA Sequencing and Next-Generation Sequencing (NGS)
- Clinical Microbiology
- Other technologies
Application
- COVID-19
- Human Immunodeficiency Virus (HIV)
- Healthcare-Associated Infections (HAIs)
- Hepatitis
- Human Papillomavirus (HPV)
- Tuberculosis (TB)
- Influenza
- Other Infectious Diseases
Application
- Diagnostic Laboratories
- Hospitals & Clinics
- Research Institutes
- Home Care Settings
- Other End Users
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies and the potential for market growth
- Abbott
- Alere Inc.
- BioMérieux SA
- Becton, Dickinson and Company
- Cepheid, Inc.
- Co-Diagnostics
- Chembio Diagnostic Systems
- Danaher Corporation
- DiaSorin S.p.A.
- ELITechGroup
- Epitope Diagnostics
- F. Hoffmann-La Roche
- Hologic, Inc.
- Grifols S.A.
- Genetic Signatures Ltd.
- InBios International
- Meridian Bioscience
- Ortho Clinical Diagnostics Holdings plc
- OraSure Technologies
- PerkinElmer Inc.
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific
- Trinity Biotech Plc.
- Trivitron Healthcare
- Uniogen Oy
- Vela Diagnostics
- Meril Life Sciences Pvt. Ltd
- Quidel Corporation.
How will the Infectious Disease Diagnostics Market, 2022 to 2032 report help you?
In summary, this 320+ page report provides you with the following knowledge:- Revenue forecasts to 2032 for Infectious Disease Diagnostics Market, 2022 to 2032 Market, with forecasts for type and company size, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2032 for five regional and 19 key national markets - See forecasts for the Infectious Disease Diagnostics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Infectious Disease Diagnostics Market, 2022 to 2032.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Infectious Disease Diagnostics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Infectious Disease Diagnostics Market Analysis by Product
5 Infectious Disease Diagnostics Market Analysis by Type of Testing
6 Infectious Disease Diagnostics Market Analysis by Technology
7 Infectious Disease Diagnostics Market Analysis by Application
8 Infectious Disease Diagnostics Market Analysis by End User
9 Infectious Disease Diagnostics Market Analysis by Region
10 North America Infectious Disease Diagnostics Market Analysis
11 Europe Infectious Disease Diagnostics Market Analysis
12 Asia Pacific Infectious Disease Diagnostics Market Analysis
13 Latin America Infectious Disease Diagnostics Market Analysis
14 MEA Infectious Disease Diagnostics Market Analysis
15 Company Profiles
16 Conclusion and Recommendations
Companies Mentioned
- Abbott Laboratories
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- BioMérieux SA
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- PerkinElmer Inc.
- Quidel Corporation.
- Siemens Healthineers
- Thermo Fisher Scientific
- Alere Inc.
- Cepheid, Inc.
- Chembio Diagnostic Systems
- Co-Diagnostics
- DiaSorin S.p.A.
- ELITechGroup
- Epitope Diagnostics
- Genetic Signatures Ltd.
- Grifols S.A.
- Hologic, Inc.
- InBios International
- Meridian Bioscience
- Meril Life Sciences Pvt. Ltd.
- OraSure Technologies
- Ortho Clinical Diagnostics Holdings plc
- Sysmex Corporation
- Trinity Biotech Plc.
- Trivitron Healthcare
- Uniogen Oy
- Vela Diagnostics
- Centers for Disease Control (CDC)
- National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID)
- National Library of Medicine
- Public Agency of Canada
- The Joint United Nations Programme on HIV/AIDS (UNAIDS)
- World Health Organization (WHO)